Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 12/20 | 0.73 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.56 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17278132 | 0.90 | SLC7A5 (0.70) | SLC7A5SLC6A4SLC6A2SLC6A3KCNK2 | |
| SCHEMBL17280857 | 0.89 | SLC7A5 (0.71) | SLC7A5SLC6A4SLC6A2SLC6A3KCNK2 | |
| SCHEMBL17278094 | 0.89 | SLC7A5 (0.71) | SLC7A5SLC6A4SLC6A2SLC6A3KCNK2 | |
| SCHEMBL17278097 | 0.89 | SLC7A5 (0.72) | SLC7A5SLC6A4SLC6A2SLC6A3KCNK2 | |
| SCHEMBL17280858 | 0.89 | SLC7A5 (0.71) | SLC7A5SLC6A4SLC6A2SLC6A3KCNK2 | |
| SCHEMBL17278137 | 0.89 | SLC7A5 (0.71) | SLC7A5SLC6A4SLC6A2SLC6A3KCNK2 | |
| SCHEMBL17278127 | 0.89 | SLC7A5 (0.68) | SLC7A5SLC6A4SLC6A2SLC6A3KCNK2 | |
| SCHEMBL17278118 | 0.89 | SLC7A5 (0.68) | SLC7A5SLC6A4SLC6A2SLC6A3KCNK2 | |
| SCHEMBL17280832 | 0.88 | SLC7A5 (0.67) | SLC7A5SLC6A4SLC6A2SLC6A3KCNK2 | |
| SCHEMBL17280831 | 0.88 | SLC7A5 (0.69) | SLC7A5SLC6A4SLC6A2SLC6A3KCNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771316-B2 | Phenoxyalkylamine compound | OSAKA UNIVERSITY (JP) | 2017-09-26 | — | — | US | disclosed |
| US-9771316-B2 | Phenoxyalkylamine compound | OSAKA UNIVERSITY (JP) | 2017-09-26 | — | — | US | disclosed |
| US-20150336876-A1 | PHENOXYALKYLAMINE COMPOUND | KNC LABORATORIES CO., LTD. (JP) | 2015-11-26 | — | — | US | disclosed |
| US-20150336876-A1 | PHENOXYALKYLAMINE COMPOUND | KNC LABORATORIES CO., LTD. (JP) | 2015-11-26 | — | — | US | disclosed |
| EP-2947066-A1 | PHENOXYALKYLAMINE COMPOUND | Osaka University (JP) | 2015-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336876-A1 | PHENOXYALKYLAMINE COMPOUND | LATS1, LATS2, SHC1 | SLC7A5 63/4885SLC6A4 413/4885SLC6A2 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.